A Randomized Trial of Rosuvastatin in Elective Angioplasty to Prevent Contrast-induced Nephropathy (CLEAR-CIN).

Phase 4 Completed 493 enrolled University of Sao Paulo Instituto Dante Pazzanese de Cardiologia · collab

RandomizedParallel-groupOpen-labelPrevention

Summary

The investigators analyzed the HMG-CoA reductase inhibitor, rosuvastatin, for the prevention of contrast-medium-induced nephropathy in patients undergoing primary angioplasty.

Timeline

Start: 2011-03
Primary completion: 2013-12
Completion: 2013-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rosuvastatin	Small molecule	40 mg	—

Indications

No indication recorded.